FGFR1 amplification and overexpression also contribute to the resistance of breast cancer cells to the CDK4/6 inhibitors used in combination with endocrine therapy in either in vitro or in vivo patient-derived xenograft models [42]. Here, CDK4 is linked to breast cancer.